Apollomics (APLM) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apollomics (APLM) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 16.6% versus a loss of 44.7%. Rein Therapeutics is the larger company by market cap ($67.9 million vs $65.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | RNTX |
|---|---|---|
| Share price | $22.50 | $0.7872 |
| Market cap | $65.59M | $67.91M |
| 1-day change | +3.69% | +2.33% |
| YTD return | +15.00% | -33.68% |
| 1-year return | +16.64% | -44.65% |
| 5-year return | — | -96.19% |
| EPS (TTM) | $-7.57 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $2.18 |
| 52-week low | $10.01 | $0.694 |
| Distance from 52-week high | -46.58% | -63.89% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +662.20% |
| Average volume | 21.69K | 430.81K |
| Shares outstanding | 2.91M | 86.27M |
| Employees | 14 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed RNTX by 61.3 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
APLM vs RNTX FAQ
Which is bigger, Apollomics or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $67.91M compared with $65.59M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or RNTX?
APLM returned +16.64% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.